Shares of Harrow, Inc. (NASDAQ:HROW – Get Free Report) traded down 5.8% on Wednesday . The company traded as low as $17.45 and last traded at $17.49. 215,167 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 464,695 shares. The stock had previously closed at $18.56. Analyst Upgrades […]
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are covering the company, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in the last year […]
Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) major shareholder Opaleye Management Inc. sold 33,000 shares of the stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $3.06, for a total transaction of $100,980.00. Following the sale, the insider now directly owns 124,250 shares of the company’s […]
HC Wainwright restated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report issued on Wednesday, Benzinga reports. The firm currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q2 2024 earnings at ($0.73) EPS, Q3 2024 earnings at ($0.74) EPS, Q4 […]
Harrow, Inc. (NASDAQ:HROW – Free Report) – B. Riley dropped their Q2 2024 earnings per share (EPS) estimates for Harrow in a research report issued to clients and investors on Tuesday, May 14th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.25) per share for the quarter, down from their previous […]